IMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW
|
|
- Cynthia Johnson
- 5 years ago
- Views:
Transcription
1 IMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW Hiren Pandya Department of Medicine, AMC MET Medical College, Ahmedabad, Gujarat, India Correspondence to: Hiren Pandya (drhirenpandya@yahoo.com) REVIEW ARTICLE DOI: /ijmsph Received Date: Accepted Date: ABSTRACT Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by a state of chronic hyperglycaemia which may lead to various disabling and life-threatening macrovascular and microvascular complications resulting in reduced quality of life and premature mortality. As per many recent evidences, Cardiovascular disease (CVD) is a major cause of morbidity and mortality in these individuals and is responsible for 70-75% of deaths in diabetes population. India is carrying almost 65 million diabetic populations with almost 77 million populations with pre-diabetes. Majority of diabetes patients suffers from dyslipidaemia. Dyslipidaemia in diabetes is usually a mixed type of hyperlipidaemia, i.e. elevated small dense LDL, high TG and low HDL-C. This pattern of dyslipidaemia is also termed as an Atherogenic Diabetic Dyslipidaemia (ADD). Current evidences suggest that elevated TG is an important independent risk factor for future CV risk. Key Words: Diabetes; Dyslipidaemia; Triglycerides; Cardiovascular Risk Introduction Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by a state of chronic hyperglycaemia which may lead to various disabling and life-threatening macrovascular and microvascular complications resulting in reduced quality of life and premature mortality. As per many recent evidences, cardiovascular disease (CVD) is a major cause of morbidity and mortality in these individuals and is responsible for 70-75% of deaths in diabetes population. India is carrying almost 65 million diabetic populations with almost 77 million populations with pre-diabetes. Majority of diabetes patients suffers from dyslipidaemia. Dyslipidaemia in diabetes is usually a mixed type of hyperlipidaemia, i.e. elevated small dense LDL, high TG and low HDL-C. This pattern of dyslipidaemia is also termed as an Atherogenic Diabetic Dyslipidaemia (ADD). Current evidences suggest that elevated TG is an important independent risk factor for future CV risk. diabetes with the greatest number of people between 40 and 59 years of age, and this equates to nearly three new cases every 10 seconds or almost 10 million per year. In the year 2013, Diabetes has been associated with 5.1 million deaths and every six seconds a person dies from it, moreover around 175 million people currently remain undiagnosed. [1] Epidemiology According to the International Diabetes Federation (IDF 2013) estimate, India ranks 2 nd in the world next to China (Figure 1) with 65.1 million people with diabetes (2013), which is expected to rise beyond million by Approximately 8.3% of adult population globally (i.e. 382 million people) have diabetes and around 80% of them live in low-and middle-income countries. By 2035, 592 million people (10.1% prevalence) will have Figure-1: IDF 2013: Top 10 countries for diabetic population (diabetic population in million) Dyslipidaemia and Diabetes (Atherogenic Diabetic Dyslipidaemia) Mixed dyslipidaemia is very common in diabetes. Dyslipidaemia associated with diabetes is increased 781 International Journal of Medical Science and Public Health 2014 Vol 3 Issue 7
2 small dense LDL-C, increased level of triglycerides (TG) and low HDL-C. Such dyslipidaemia is associated with increased progression of atherosclerosis, hence called Atherogenic Diabetic Dyslipidaemia (ADD). In a study done on Indian diabetic population (Figure 2), dyslipidaemia was present in 85.5% males and 97.2% females. [2] dyslipidemia which makes them more prone to atherosclerosis. A study on Asian Indians living in the United States found that 54% of Indian men and 68% of Indian women had relatively lower levels of HDL-C, and 43% of Indian males and 24% of females have relatively higher TG levels (>150 mg/dl). [3] Dyslipidemia and CV Risk: As the INTERHEART study have shown, dyslipidemia is the single most important CV risk factor accounting for almost 50% of first myocardial infarction worldwide [4] and this risk is increased 3-4 times if there is associated diabetes along with dyslipidemia [5]. Hypertriglyceridemia as a Cardiovascular Risk Factor in Diabetes Figure-2: Prevalence of dyslipidaemia in male and female diabetic patients in India [2] Factors Contributing to Higher Incidence of Dyslipidaemia in Indian Population There are many lifestyle and genetic related factors associated with higher incidence of dyslipidemia in Indian population [3,4] : Physical inactivity Dietary habits Indian diet is rich in carbohydrate and low in omega-3 PUFA- exacerbates hypertriglyceridemia. Obesity - Indians have excessive body fat and more abdominal adiposity which is harmful even if BMI is under control. Excess body fat in relation to body mass index Abnormal variants of Apo C3 (causing lipoprotein lipase inhibition) and ApoE3 (formation of VLDL) genes are common in India which can lead to dyslipidemia Thrifty gene ("Starvation Gene Theory")- India suffered droughts for hundreds of years, so the genes were adapted to survive long periods of drought by consuming fats and carbohydrates slowly to make them last longer. Now in spite of adequate supplies of food, these genes are still active. So food continues to be metabolised slowly resulting in the dysfunctional biochemical profile that constitutes Syndrome X. Dyslipidemia Indian vs. Western: Indians, as compared to the Western counterpart, have a different pattern of There are plenty of evidence indicating direct relationship between LDL-C and cardiovascular morbidity and mortality. But, there has been more uncertainty regarding the association between high triglyceride (HTG) levels and CVD. One of the important component of metabolic syndrome is high triglyceride level. In recent past, evidences indicating direct relation between high TG and CV risk are mounting. Table 1 demonstrates classification of HTG. [6] Table-1: Classification of fasting triglycerides levels Fasting Triglycerides Levels Category < 150 mg/dl Normal mg/dl Borderline high mg/dl High >500 mg/dl Very High Hypertriglyceridemia is usually clinically asymptomatic but patients may present with eruptive xanthoma, hepatosplenomegaly, lipeamia retinalis, abdominal pain. When triglyceride levels are very high ( 500 mg/dl), the risk of pancreatitis, peripheral neuropathy, dyspnoea, memory loss and dementia increases. [7] As per the results of a meta-analysis of 17 prospective studies (> 55,000 patients), for every increase in TG level of 89 mg/dl, CVD risk increases by 32% in men and 76% in women. This suggests that hypertriglyceridemia is an independent risk factor for CVD. [8] A recent and larger meta-analysis of 29 prospective studies involving 2,62,525 participants reported that there is a strong and highly significant association between triglyceride levels and cardiovascular risk in diabetics even after adjustment for HDL-C. The study yielded an adjusted odds ratio of 1.72 (95% CI, International Journal of Medical Science and Public Health 2014 Vol 3 Issue 7
3 1.90) in a comparison of extreme thirds of usual triglyceride values i.e., individuals with usual logtriglyceride values in the top third of the population compared with those in the bottom third suggesting that patients in highest tertile of serum TG had 72% higher risk of CVD than those in lowest tertile. [9] (Figure 3) hypertriglyceridemia (independent of and cumulative to the effect of hyperglycemia) on endothelial function. [12] Hypertriglyceridemia and Increased CV Risk Hypertriglyceridemia is associated with increased insulin secretion, suggesting a direct relation of TG with the insulin resistance. [13] Figure-3: Risk of CHD (coronary heart disease) in individuals in the top vs bottom third of usual log-triglyceride values grouped according to several study characteristics in a meta-analysis of 29 prospective studies As per an Asian study of diabetic patients who were followed up for 4.6 years, high TGs in diabetes increase cardiovascular risk by 3 times compared to diabetic patients without high TG. [10] Liu et al carried out a study showing that elevated blood TG levels were dose-dependently associated with higher risks of CVD and all-cause mortality. Compared to the referent ( mg/dl) group, the pooled relative risks ratio of CVD mortality for the lowest (< 90 mg/dl), borderline-high ( mg/dl), and high TG ( 200 mg/dl) groups were 0.83, 1.15, and 1.25 respectively. For total mortality they were 0.94, 1.09, and 1.20, respectively. The risks of CVD and all-cause deaths were increased by 13% and 12% (p < 0.001) respectively per 1-mmol/L (89 mg/dl) increase in TG levels. [11] The Copenhagen City Heart Study also reported that nonfasting TG levels were associated with increased risk of myocardial infarction, ischemic heart disease, and death after adjustment for age, total cholesterol, BMI, hypertension, diabetes, smoking, alcohol consumption, physical inactivity, lipid-lowering therapy, postmenopausal status, and hormone therapy in women. The levels of non-fasting TG were highly correlated with those of remnant lipoprotein cholesterol. These results may also reflect the effect of postprandial Further, High TG level is directly proportaionate to increased small dense LDL particle. A threshold appears to exist for a fasting TG concentration above which there is predominance of small dense LDL particles and below which large, more buoyant particles predominate. At a fasting TG concentration of 100 mg/dl, 85% of the population has predominant large buoyant LDL particles (phenotype A), whereas at a fasting TG concentration of 250 mg/dl, 85% have has predominant sd LDL-C particles (phenotype B). Most patients have a threshold for shifting LDL-C subclass pattern within the range of 100 to 250 mg/dl and since sd LDL-C is known to be more atherogenic, therefore keeping TG even at may not reduce atherosclerosis completely. A target of TG < 100 mg/dl should therefore be considered. [14] Hypertriglyceridemia is also associated with low HDL-C levels and association between reduced HDL cholesterol levels and increased risk of heart disease is well established. [15] Hypertriglyceridemia is usually associated with rise in fibrinogen and plasma plasminogen activator inhibitor leading to a prothrombic state. [19] Hypertriglyceridemia is also associated with Pro-inflammatory state as it is associated with increase in the level of C-reactive protein. [19] TG Reduction and Cardiovascular Benefits VA-HIT Study: it was found that gemfibrozil given to 627 diabetic patients resulted in 24% reduction in the expanded end point of death from CHD, nonfatal myocardial infarction (MI), and confirmed stroke which was significant (P = 0.05) as compared to placebo. [16] In a subsequent report, in which the diagnosis of diabetes was modified to include the new criteria of fasting plasma glucose 126 mg/dl, the total cohort of diabetic patients was increased to 769 and there was a 32% risk reduction of the composite end point of CHD death, stroke, or MI (P = 0.004). This decrease was largely due to a reduction in CHD deaths due to triglyceride reduction. [17] 783 International Journal of Medical Science and Public Health 2014 Vol 3 Issue 7
4 BIP Study: (Bezafibrate in patients with TG > 200 mg/dl) 3090 CAD patients were followed up for 6.2 years. Bezafibrate use showed a very significant 39.7% reduction in CV events (primary end point was fatal, nonfatal MI/sudden death) as compared to placebo. [18] In the Diabetes Atherosclerosis Intervention Study (DAIS), 418 T2DM patients were randomized for 3 years to fenofibrate (200 mg/d) or placebo treatment. A significant reduction in triglycerides, LDL-C, and increase in HDL-C were observed in the fenofibrate treated group. There was significantly less coronary angiographic progression in atheroma volume and diameter and percent diameter stenosis, and a decrease in the incidence of microalbuminuria. [19] HHS Study: In the Helsinki Heart Study, treatment with gemfibrozil resulted in a 71% lower incidence of CHD events in the subgroup of patients free of CHD at baseline, with the TG level >200 mg/dl and LDL cholesterol/hdl cholesterol ratio above 5. [20] Recent Trials for TG Reduction and CV Outcome (FIELD and ACCORD Trials) FIELD and ACCORD trials do not provide benefits in their primary end points but the sub-analyses of the above two trials showed benefit in patients with high baseline TG and low HDL. FIELD Trial comprised of 9795 type 2 diabetes patients of years age who were followed for five years with no clear indication for cholesterollowering therapy at baseline (total cholesterol mg/dl, plus either total cholesterol to HDL ratio 4.0 or triglyceride >88.6 mg/dl). Fenofibrate reduced total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations but the difference in primary outcome was insignificant between the two groups. [21] However a sub-analysis of the subgroups of more than 2000 patients with high TG (> 200 mg/dl) showed that fenofibrate significantly reduced CV events by 27% concluding that fenofibrate do reduce CV events in T2DM patients when the baseline TG are high. [22] Similar results were reported in ACCORD trial where 5518 patients with T2DM (HbA1c> 7.5%) were given fenofibrate or placebo. All patients were on simvastatin at baseline and followed up for 4.7 years. The annual rate of the primary outcome was not reduced significantly (p = 0.32). [23] But when sub-analyzed in 941 patients (out of 5518) with both a high baseline triglyceride level (TG>204 mg/dl) and a low baseline level of HDL (<34 mg/dl), fenofibrate reduced primary end point significantly by 31%. [24] Meta-analysis: In a meta-analysis of 5 landmark studies (ACCORD, FIELD, BIP, VA-HIT and HHS) involving 4726 patients, fibrates have been found to reduced CV events significantly by 35% in patients with high TG 204 mg/dl and low HDL 34 mg/dl (atherogenic dyslipidaemia). [25] Conclusion In India, diabetes and related complications are increasing rapidly. Majority of diabetic patients in India do suffer from dyslipidaemia. Diabetic dyslipidaemia in India is usually a mixed type, i.e. increased small dense LDL, high TG and low HDL. These may be due to different ethnicity and poor lifestyle. High TG is independently associated with increased risk of cardiovascular morbidity and mortality. ACCORD and FIELD study failed to show any CV outcome benefits with TG lowering therapy with fenofibrate. But, we need to remember that baseline TG in both these studies was very close to normal (i.e. around 160 mg/dl). Subgroup analysis of FIELD and ACCORD studies (in patients population with high TG and low HDL at baseline) have shown significant CV risk reduction with Fibrates. Meta-analysis of 5 large trials also suggests the same. Indian population is different from Caucasian. High TG and low HDL is important risk factors in Indian. Treatment of high TG improves long term CV outcome. References 1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, Parikh RM, Joshi SR, Menon PS, Shah NS. Prevalence and pattern of diabetic dyslipidemia in Indian type 2 diabetic patients. Diabetes Metab Syndr. 2010;4: Clinical Implications: Dyslipidemia in the Asian Indian Population. Unique aspects and implications for treatment. 20th Annual Convention of the American Association of Physicians of Indian Origin. June 29, Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364: Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final 784 International Journal of Medical Science and Public Health 2014 Vol 3 Issue 7
5 report. Circulation 2002:106: Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med. 1992;37: Hokanson J, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3: Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115: Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, et al Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev 2005;21: Liu J, Zeng FF, Liu ZM, Zang CX, Ling WH, Chen YM. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis 2013;12: Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;98: Olefsky JM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974;57: Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990; 82: Miller M. Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J 1998;19:H Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341: Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs highdensity lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162: Bezafibrate Infarction Prevention (BIP) study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102: Steiner G, Hamsten A, Hosking J, Stewart D, McLaughlin P, Gladstone P, et al. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357: Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85: Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366: Scott R, O Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, et al; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32: Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362: Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012;11: Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363: Cite this article as: Pandya H. Importance of high triglycerides as a cardiovascular risk factor in indian diabetic population A review. Int J Med Sci Public Health 2014;3: Source of Support: Nil Conflict of interest: None declared 785 International Journal of Medical Science and Public Health 2014 Vol 3 Issue 7
The American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationWhen it comes to the FIELD study, what is...is
Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tlip19 When it comes to the FIELD study, what is...is James McKenney To cite this article: James McKenney
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationA Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/21 A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Bingi Srinivas
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationAlthough medical advances have curbed
PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationMetabolic Syndrome.
www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present
More informationRecent Advances & Emerging Data in the Treatment of Hypertriglyceridemia. Michael Miller, MD, FACC, FAHA, FNLA
Recent Advances & Emerging Data in the Treatment of Hypertriglyceridemia Michael Miller, MD, FACC, FAHA, FNLA Professor of Medicine, Epidemiology & Public Health University of Maryland School of Medicine
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationEFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL
Thi-Qar Medical Journal (TQMJ): Vol(5) No(2):2011(39-44) EFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL Dr. Akeel bal-yaqobi *, Dr.
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationThe Cardiovascular Institute Mount Sinai School of Medicine, New York
The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More informationHyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
...PRESENTATIONS... Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Based on a presentation by Ronald B. Goldberg, MD Presentation Summary Atherosclerosis accounts for approximately
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationUse of Subgroups to Rescue a Trial or Improve Benefit-Risk
1 Use of Subgroups to Rescue a Trial or Improve Benefit-Risk Martin King, Ph.D. Director, Statistics Global Pharmaceutical R&D, Abbott Abbott Park, IL USA 2 Disclaimer The opinions in this presentation
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationFrequency of Dyslipidemia and IHD in IGT Patients
Frequency of Dyslipidemia and IHD in IGT Patients *Islam MS, 1 Hossain MZ, 2 Talukder SK, 3 Elahi MM, 4 Mondal RN 5 Impaired glucose tolerance (IGT) is often associated with macrovascular complications.
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationFibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr
Fibrate and cardiovascular disease: Evident from meta-analysis Thongchai Pratipanawatr ??? ย คห นใหม ย คห นกลาง ย คห นเก า ?? Statin era? ย คห นใหม ย คห นกลาง ย คห นเก า CURRENT ROLE OF FIBRATE What are
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationElevated low-density lipoprotein
A for Simvastatin and Gemfibrozil Molly Haselden, PharmD, BCPS; Thomas Worrall, PharmD, BCPS; and Dorothy Jenrette, PharmD, BCPS Eliminating gemfibrozil from a statin-containing regimen may be safe and
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationLow HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationORIGINAL INVESTIGATION. Gemfibrozil in the Treatment of Dyslipidemia. An 18-Year Mortality Follow-up of the Helsinki Heart Study
ORIGINAL INVESTIGATION Gemfibrozil in the Treatment of Dyslipidemia An 18-Year Mortality Follow-up of the Helsinki Heart Study Leena Tenkanen, PhD; Matti Mänttäri, MD; Petri T. Kovanen, MD; Hanna Virkkunen,
More informationBACKGROUND: The association between
DOI: 10.18585/inabj.v9i1.266 Association between Cardiovascular Risk and Elevated Triglycerides (Sargowo D, et al.) REVIEW ARTICLE The Association between Cardiovascular Risk and Elevated Triglycerides
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationraised triglycerides and residual cardiovascular risk
EARN 3 FREE CPD POINTS cardiovascular Leader in digital CPD for Southern African healthcare professionals Prof Dirk Blom University of Cape Town Heart Centre and Lipid Clinic Groote Schuur Hospital raised
More informationIt is currently estimated that diabetes prevalence by
clinical Study The Prevalence and Pattern of Dyslipidemia among Type 2 Diabetic Patients at Rural Based Hospital in Gujarat, India Hetal Pandya*, JD Lakhani**, J Dadhania, A Trivedi Abstract Only proper
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationAssessment of clinical profile of coronary artery disease in Indian Population
Original article: Assessment of clinical profile of coronary artery disease in Indian Population 1Dr J S Dhadwad, 2 Dr N G Karandikar 1 Assistant Professor, Department of Medicine, P. Dr. D Y Patil Medical
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationThe Metabolic Syndrome
The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,
More informationEXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION
1 A STUDY ON THE EFFECT OF DIET & LIFE STYLE ON THE INCIDENCE OF CORONARY ARTERY DISEASE IN MODERATELY DRINKING EX MILITARY MEN IN PATHANAMTHITTA DISTRICT. EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT
More informationDiabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions
Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes is one of the largest global health emergencies of 21 st century, with the number of people with
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationThe IDF consensus worldwide definition of the metabolic syndrome
International Diabetes Federation Avenue Emile De Mot 19 B-1000 Brussels, Belgium Telephone +32-2-5385511 Telefax +32-2-5385114 info@idf.org www.idf.org VAT BE433.674.528 The IDF consensus worldwide definition
More informationAggressive Lipid Management for Diabetes
Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More information